Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

André Oberthuer, Matthias Fischer(Goethe University Frankfurt), Andreas Faldum(University of Münster), Carolina Sterz(University of Cologne), Monika Ortmann(University of Cologne), Frank Westermann(German Cancer Research Center), Smadar Avigad(Schneider Children's Medical Center), Miki Ohira(Saitama Cancer Center), Olivier Delattre(Institut Curie), Frank Speleman(Ghent University), Isaac Yaniv(Tel Aviv University), Roland Eils(Heidelberg University), Frank Berthold(University of Cologne), Gian Paolo Tonini(Città della Speranza Foundation), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Benedikt Brors(German Cancer Research Center), Isabelle Janoueix‐Lerosey(Inserm), Akira Nakagawara(Asia Centre), Rosa Noguera(Universitat de València), Ruth Volland(University Hospital Cologne), Richard G. Grundy(Brain Tumour Research), Robert C. Seeger(Ottawa Hospital), Marta Piqueras(Universitat de València), Barbara Hero(University Hospital Cologne), Paola Scaruffi(Azienda Ospedaliera S.Maria), Thorsten Simon(University of Cologne), Yvonne Kahlert(University of Cologne), Jo Vandesompele(Ghent University), Gudrun Schleiermacher, Shahab Asgharzadeh(Children's Hospital of Los Angeles), René Schmidt(University of Münster), Chunxuan Shao(German Cancer Research Center), Jean Bénard(Institut Gustave Roussy), Manfred Schwab(German Cancer Research Center), Anne Engesser(University Hospital Cologne), Alexander Valent(Institut Gustave Roussy), Jessica Theißen(University Hospital Cologne)
Unknown
March 31, 2023
Cited by 0


Related Papers